Moore R Andrew, Gay-Escoda C, Figueiredo R, Tóth-Bagi Z, Dietrich T, Milleri S, Torres-Lagares D, Hill C M, García-García A, Coulthard P, Wojtowicz A, Matenko D, Peñarrocha-Diago M, Cuadripani S, Pizà-Vallespir B, Guerrero-Bayón C, Bertolotti M, Contini M P, Scartoni S, Nizzardo A, Capriati A, Maggi C A
Pain Research and Nuffield Division of Anaesthetics, Nuffield Department of Clinical Neurology, University of Oxford, The Churchill, Oxford, OX3 7LE, UK,
J Headache Pain. 2015;16:541. doi: 10.1186/s10194-015-0541-5. Epub 2015 Jun 27.
Combination analgesics are effective in acute pain, and a theoretical framework predicts efficacy for combinations. The combination of dexketoprofen and tramadol is untested, but predicted to be highly effective.
This was a randomised, double-blind, double-dummy, parallel-group, placebo-controlled, single-dose trial in patients with moderate or severe pain following third molar extraction. There were ten treatment arms, including dexketoprofen trometamol (12.5 mg and 25 mg) and tramadol hydrochloride (37.5 mg and 75 mg), given as four different fixed combinations and single components, with ibuprofen 400 mg as active control as well as a placebo control. The study objective was to evaluate the superior analgesic efficacy and safety of each combination and each single agent versus placebo. The primary outcome was the proportion of patients with at least 50 % max TOTPAR over six hours.
606 patients were randomised and provided at least one post-dose assessment. All combinations were significantly better than placebo. The highest percentage of responders (72%) was achieved in the dexketoprofen trometamol 25 mg plus tramadol hydrochloride 75 mg group (NNT 1.6, 95% confidence interval 1.3 to 2.1). Addition of tramadol to dexketoprofen resulted in greater peak pain relief and greater pain relief over the longer term, particularly at times longer than six hours (median duration of 8.1 h). Adverse events were unremarkable.
Dexketoprofen trometamol 25 mg combined with tramadol hydrochloride 75 mg provided good analgesia with rapid onset and long duration in a model of moderate to severe pain. The results of the dose finding study are consistent with pre-trial calculations based on empirical formulae.
EudraCT (2010-022798-32); Clinicaltrials.gov (NCT01307020).
复方镇痛药对急性疼痛有效,且有一个理论框架预测了复方制剂的疗效。右酮洛芬和曲马多的复方制剂尚未经过测试,但预计疗效显著。
这是一项随机、双盲、双模拟、平行组、安慰剂对照的单剂量试验,研究对象为拔除第三磨牙后出现中度或重度疼痛的患者。试验设有10个治疗组,包括右酮洛芬氨丁三醇(12.5毫克和25毫克)和盐酸曲马多(37.5毫克和75毫克),以四种不同的固定复方制剂和单一组分给药,同时设布洛芬400毫克作为阳性对照以及一个安慰剂对照。研究目的是评估每种复方制剂和每种单一组分相对于安慰剂的镇痛效果及安全性。主要结局指标为在6小时内最大总疼痛缓解率至少达到50%的患者比例。
606例患者被随机分组并至少提供了一次给药后评估。所有复方制剂均显著优于安慰剂。右酮洛芬氨丁三醇25毫克加盐酸曲马多75毫克组的应答者比例最高(72%)(需治疗人数为1.6,95%置信区间为1.3至2.1)。在右酮洛芬中添加曲马多可带来更大的疼痛峰值缓解以及更长期的疼痛缓解,尤其是在超过6小时的时间段(中位持续时间为8.1小时)。不良事件不显著。
右酮洛芬氨丁三醇25毫克联合盐酸曲马多75毫克在中度至重度疼痛模型中提供了起效迅速且持续时间长的良好镇痛效果。剂量探索研究的结果与基于经验公式的试验前计算结果一致。
EudraCT(2010 - 022798 - 32);Clinicaltrials.gov(NCT01307020)。